7-OH’s Unlikely Users: A Cautionary Tale of Regulated Addiction

The DEA’s impending ban on 7-hydroxymitragynine, a potent compound found in kratom, has left its user base reeling. As the agency prepares to classify it as a Schedule I substance alongside heroin and fentanyl, some users are stockpiling the substance and seeking advice online on how to taper off before the ban takes effect.

For Cam, who was severely injured in a motorcycle accident and subsequently became reliant on 7-OH for pain relief, the news has sparked anxiety. Many others have reported feeling dependent on the substance, which they’ve used to self-medicate chronic pain. The DEA’s decision comes as no surprise, given concerns about the unregulated dietary supplement industry and the risk of abuse associated with 7-OH.

The kratom lobby is taking a different stance, arguing that 7-OH should not be classified as kratom because it’s much more potent. This highlights the complex web of interests surrounding this substance. The fact that kratom itself will likely remain unaffected by the ban raises questions about the motives behind the DEA’s actions.

Some users have reported positive experiences with 7-OH, but others have suffered from severe withdrawal symptoms after stopping use. Archie, a pharmacy student who used the substance to treat pain stemming from an abscess in his jaw, describes the experience as “severe” and notes that he couldn’t function without it. His story is not unique – many users report feeling unable to cope with everyday life without their 7-OH fix.

The implications of this ban are far-reaching. With a two-year temporary ban set to take effect on August 5, some users may turn to black market sources or other unregulated substances in search of relief. The consequences could be dire – Cam fears that the ban will lead to a spike in overdose deaths as users return to street opioids.

The DEA’s actions also raise questions about the role of regulation in addressing addiction. While the agency is taking steps to mitigate risks associated with 7-OH, some critics argue that this approach only serves to drive the problem underground. As one user noted on Reddit, “They’re fucking a lot of people” – a sentiment that reflects frustration and desperation felt by many in the 7-OH community.

The unregulated supplement industry has been highlighted as a major vulnerability due to lack of federal oversight or safety standards. Companies are free to market whatever they like, including substances with potentially deadly side effects. The fact that kratom itself will remain unaffected by the ban raises questions about the DEA’s priorities and whether this decision is truly motivated by concerns for public health.

The kratom lobby has long maintained that 7-OH should not be classified as kratom due to its potency. While some argue that this distinction is justified, others see it as an attempt to deflect responsibility for problems associated with 7-OH. The fact that the Trump administration has sided with the kratom lobby only serves to further muddy the waters.

At the heart of this story are individuals like Cam and Archie – people who have become reliant on 7-OH as a result of chronic pain or injury. Their experiences serve as a stark reminder of the human cost of addiction and the importance of addressing root causes rather than simply regulating symptoms.

As we watch this story unfold, it’s clear that the consequences of the 7-OH ban will be far-reaching – and may ultimately lead to more harm than good. The DEA must carefully consider the potential impact on users like Cam and Archie, who rely on the substance for pain relief. By examining the broader implications of this decision and working towards creating more effective solutions to address addiction and public health, we can hope to mitigate some of the damage already done.